Bradley Foster & Sargent Inc. CT Buys Shares of 42,066 DENTSPLY SIRONA Inc. $XRAY

Bradley Foster & Sargent Inc. CT purchased a new stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 42,066 shares of the medical instruments supplier’s stock, valued at approximately $534,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in DENTSPLY SIRONA in the first quarter worth approximately $26,000. Parkside Financial Bank & Trust increased its holdings in shares of DENTSPLY SIRONA by 620.6% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 1,477 shares during the period. True Wealth Design LLC raised its position in shares of DENTSPLY SIRONA by 273.0% in the 2nd quarter. True Wealth Design LLC now owns 2,376 shares of the medical instruments supplier’s stock worth $38,000 after acquiring an additional 1,739 shares in the last quarter. Central Pacific Bank Trust Division lifted its stake in shares of DENTSPLY SIRONA by 100.0% during the 3rd quarter. Central Pacific Bank Trust Division now owns 4,000 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Versant Capital Management Inc boosted its position in DENTSPLY SIRONA by 878.6% during the third quarter. Versant Capital Management Inc now owns 4,883 shares of the medical instruments supplier’s stock valued at $62,000 after purchasing an additional 4,384 shares in the last quarter. 95.70% of the stock is currently owned by institutional investors.

DENTSPLY SIRONA News Roundup

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Q4 sales topped estimates — reported net sales of $961M (up 6.2% y/y; beat Street sales estimates), which triggered an initial stock rally. Dentsply Sirona’s (NASDAQ:XRAY) Q4 CY2025 sales top estimates, stock soars
• Positive Sentiment: Company announced a Return-to-Growth Action Plan redirecting ~ $120M annually toward innovation, clinical education and sales — a capital reinvestment that management says is aimed at accelerating revenue growth. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook
• Positive Sentiment: New commercial moves — updated distributor agreements (Patterson, Benco, Burkhart, A-dec) and a U.S. product entry (Surity™ female external catheter) add distribution breadth and product diversification. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook
• Positive Sentiment: Board refresh — appointment of three experienced directors (former Morgan Stanley, IDEXX CFO, and Patterson CEO) could strengthen governance and execution of the turnaround. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook
• Neutral Sentiment: Adjusted EPS was $0.27 (in line with management’s adjusted figure but missed the consensus by $0.01); revenue growth is positive year-over-year — investors will watch margin recovery under the turnaround plan. Dentsply (XRAY) Reports Q4 Earnings: What Key Metrics Have to Say
• Negative Sentiment: GAAP net loss of $146M (diluted loss $0.74) was driven by ~$144M of goodwill and intangible impairments — the large non‑cash charge clouds near-term reported profitability. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook
• Negative Sentiment: FY-2026 guidance shows adjusted EPS $1.40–1.50 (near consensus) but revenue guidance $3.5–3.6B is below the ~$3.7B consensus; management also eliminated the dividend to fund debt reduction and buybacks — a capital-allocation shift that may concern income investors. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook
• Negative Sentiment: Halper Sadeh LLC announced an investigation into whether officers/directors breached fiduciary duties — introduces legal/management uncertainty. HALPER SADEH LLC ENCOURAGES DENTSPLY SIRONA INC. SHAREHOLDERS TO CONTACT THE FIRM

DENTSPLY SIRONA Trading Down 0.7%

NASDAQ XRAY opened at $12.71 on Friday. The company has a fifty day moving average of $12.35 and a 200 day moving average of $12.47. The company has a market capitalization of $2.54 billion, a PE ratio of -2.88, a P/E/G ratio of 1.01 and a beta of 1.01. The company has a debt-to-equity ratio of 1.36, a current ratio of 1.47 and a quick ratio of 0.99. DENTSPLY SIRONA Inc. has a 1 year low of $9.85 and a 1 year high of $19.03.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 24.34% and a positive return on equity of 17.10%. The company had revenue of $961.00 million during the quarter, compared to analyst estimates of $926.40 million. During the same period last year, the firm earned $0.26 EPS. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Research analysts forecast that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current year.

DENTSPLY SIRONA Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 9th. Investors of record on Friday, December 26th were given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 5.0%. The ex-dividend date was Friday, December 26th. DENTSPLY SIRONA’s dividend payout ratio is -14.48%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on XRAY. UBS Group reduced their target price on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Barrington Research reissued an “outperform” rating and set a $14.00 target price on shares of DENTSPLY SIRONA in a research report on Monday, January 5th. Mizuho raised their target price on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Tuesday, January 20th. Barclays initiated coverage on DENTSPLY SIRONA in a research report on Monday, December 8th. They set an “underweight” rating and a $12.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of DENTSPLY SIRONA in a research report on Wednesday, January 21st. Three research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, DENTSPLY SIRONA has a consensus rating of “Hold” and an average price target of $14.46.

Insiders Place Their Bets

In other DENTSPLY SIRONA news, Director Gregory T. Lucier sold 82,200 shares of the stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $11.14, for a total transaction of $915,708.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.50% of the company’s stock.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.